SAN DIEGO, CA / ACCESSWIRE / March 19, 2020 / Nascent Biotech, Inc. (NBIO), today announced it has begun research on a possible treatment for patients infected with COVID-19. As previously mentioned in the scientific literature (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) Pritumumab’s specific target, cell surface vimentin, is a potential target in the treatment of conditions related to COVID-19.

Nascent founder and Advisory Board Chairman, Dr. Mark Glassy, commented, “As previously announced, we have known for some time that the receptor for Nascent’s lead asset, Pritumumab, may also be a receptor used by viruses for infection, and we have begun In Vitro studies this week. Shortly, we will have indications into what further research will be required to determine the effectiveness of Pritumumab as a potential therapeutic. As planned, testing has begun on the ability of Pritumumab to interfere with the virus’ binding to its target cells and provide treatment against this devastating pandemic.”

“Engaging in the fight against COVID-19 is the first step in further optimizing this promising drug, which already has implications in treating deadly disease such as brain and pancreatic cancers.” said Dr. Glassy.

About Nascent Biotech Inc

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website

Safe Harbor:

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Sean Carrick
President | CEO
Nascent Biotech, Inc

6330 Nancy Ridge Dr
Suite 105
San Diego CA 92121
(612) 961-5656